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The main drawbacks are mentioned by a lower percent of 
participants: 
·        There are no institutional support and resources to 
make the analysis (71% of RO, 56% of MP and 33% of RTT). 
·        Time needed (86% of RO, 44% of MP and 50% of RTT). 
·        Very few indicate that it cannot detect the safety weak 
points (14% of RO), results are qualitative and subjective 
(17% of RTT) or that the risk analysis has not the depth 
needed (33% of MP). 
The software used (SEVRRA) was considered as a tool easy to 
use that facilitates the analysis by 71% of RO, 89% of MP and 
67% of RTT. 
Conclusions: The risk matrix is a proven tool for risk analysis 
in radiotherapy.  To implement a risk methodology among 
radiotherapy professionals it is very important that everyone 
who takes part in the process is involved in the risk analysis. 
The working group needs basic training before they can start 
it and assistance from risk analysis experts. 
Training a reduced number of radiotherapy centers, that can 
eventually act as reference centers at local level, is a 
feasible and effective way of spreading the use of these 
techniques at national level. 
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Introduction: Patient safety in radiotherapy is a 
comparatively new discipline that has rapidly risen to star 
status. This rise began in the late 1990s, with eye-opening 
reports documenting the scale of harm caused by medical 
errors. In 2010, the New York Times published a series of 
articles on medical errors elevating the awareness of 
accidents in radiotherapy. Safe radiotherapy requires a multi-
disciplinary comprehensive approach to assure that an 
adequate safety system is in place.  One aspect of a robust 
safety system is the identification of near misses and errors 
that occur in radiotherapy.  The use of an incident learning 
system can capture data that can be used to identify 
weakness in safety and provide the institution with 
information in the use of effective safety barriers. 
Institutions can also look at the potential for harm and 
identify safety infrastructure needs using prospective risk 
analysis such as Failure Mode and Effects Analysis (FMEA). 
These types of analytical tools assist in understanding the 
adequacy of the safety system by addressing the potential for 
errors, the frequency of the errors and the severity of the 
errors. Both reporting and learning systems and prospective 
analysis have value in patient safety, but to elevate their 
effectiveness, the institution should consider looking at 
industry wide activities and results.  Benchmarking can be 
used to compare one institution’s safety system and 
performance metrics to industry standards.  The IAEA Safety 
in Radiation Oncology (SAFRON) Incident Learning system can 
provide both institutional data and global data on potential 
errors.  The system is in the process of implementing a 
prospective risk analysis option that will allow the participant 
to address the likelihood of an event to happen at their 
institution based on initiating events, barriers and 
consequences. 
Purpose/Objective: Provide information of the tools that are 
available to improve safety in radiotherapy, including: 
·   retrospective studies to include incident learning systems, 
·   prospective studies to identify potential for harm, and 
·   use of benchmarking to evaluate safety systems against 
institutional standards. 
Material/methods: Lecture to include demonstration of the 
effectiveness in reducing radiotherapy incidents by 
evaluating past incidents, prospective risk analysis and 
benchmarking. 
Results: Participants will have knowledge on the use of these 
safety tools that can be incorporated into the clinical 
environment and knowledge on how to evaluate their safety 
system. 
Conclusion: A robust safety system in radiotherapy requires a 
multi-disciplinary comprehensive approach that includes 
evaluating events within the institution, evaluating the 
potential for harm and comparing these activities to 
institutional standards in radiotherapy.  This can best be 
accomplished by participating in an incident learning system, 
conducting prospective risk analysis and benchmarking these 
results. 
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The first recorded use of heat to treat cancer was made some 
5000 years ago, thus making it one of the oldest cancer 
therapies known. But, when using heat as a single agent 
therapy, tumour control is only likely when very high thermal 
ablation temperatures are achieved. At lower temperatures 
in the hyperthermia range (typically temperatures of up to 
around 43OC) tumour control is not possible. As a result, 
hyperthermia is often considered an experimental treatment 
with no realistic future in clinical cancer therapy. This is 
wrong. Although hyperthermia per se is probably only useful 
in palliative situations and has no role to play in the curative 
treatment of human tumours, there is definitive evidence 
that when hyperthermia is combined with more conventional 
therapies significant improvements in clinical outcome are 
possible. This is especially true for the combination of 
hyperthermia and radiation, and in fact, hyperthermia is 
probably one of the most effective radiation sensitizers 
known. In this presentation, we will review the pre-clinical 
studies establishing the rationale for how hyperthermia 
should be combined with conventional therapies and present 
an update of the clinical results demonstrating the clear 
benefit of such combination treatments in patients with 
specific types of cancer. In addition, we will discuss what 
approaches are now being applied to further improve the 
efficacy of hyperthermia when combined with more 
conventional therapies. 
